2022
1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, Malhotra J, Chawla N, Lyou Y, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald B, Trent J, Murtaza M, Pal S. 1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC). Annals Of Oncology 2022, 33: s1223. DOI: 10.1016/j.annonc.2022.07.1582.Peer-Reviewed Original Research
2021
Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2021, 27: 4807-4813. PMID: 34130999, DOI: 10.1158/1078-0432.ccr-21-0572.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCell-free tumor DNARenal cell carcinomaGenomic profilingCell carcinomaTissue-based testingTumor DNA (ctDNA) assessmentClinical Laboratory Improvement AmendmentsActionable alterationsCtDNA profilingCtDNA assessmentPatientsTumor DNAUnique alterationsAlteration frequencyCarcinomaDNA assessmentBloodGreater temporal separationTissueAlterationsConcordancePrevious findingsMutationsConcordance analysisIllustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data.
Zengin Z, Weipert C, Hsu J, Salgia N, Hensel C, Maughan B, Rathi N, Goel D, Agarwal N, Choueiri T, Pal S. Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Journal Of Clinical Oncology 2021, 39: 347-347. DOI: 10.1200/jco.2021.39.6_suppl.347.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaGenomic profilingCtDNA alterationsMost common histologySubset of ptsRenal cell carcinomaSeparate validation cohortTissue-based assessmentProportion of alterationsCommon histologyMedian timeValidation cohortCell carcinomaCtDNA assessmentClear cellsCtDNA analysisTumor DNACohortGene panelTissue samplesTissue assessmentMonthsOnly alterationSignificant differencesPatients
2020
Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
Zengin Z, Weipert C, Hsu J, Salgia N, Saam J, Choueiri T, Agarwal N, Pal S. Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. Annals Of Oncology 2020, 31: s553-s554. DOI: 10.1016/j.annonc.2020.08.773.Peer-Reviewed Original ResearchCirculating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC).
Zengin Z, Dizman N, Salgia N, Jones J, Zhang J, Liu Y, Xu B, Li F, Wang Y, Li M, Du R, Zhou Y, Hsu J, Salgia M, Yang L, Pal S. Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2020, 38: e17100-e17100. DOI: 10.1200/jco.2020.38.15_suppl.e17100.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRelevant genomic alterationsRenal cell carcinomaGenomic alterationsCell carcinomaPathway alterationsCtDNA next-generation sequencingLines of therapyClear cell histologyMTOR pathway alterationsRate of concordanceCell histologyMedian ageSingle institutionTreatment sequencingClinicopathologic variablesCancer DatabaseCtDNA assessmentInvasive approachUrine specimenBlood specimensCtDNA studiesPatient databasePathogenic alterationsTumor DNA